Feasibility study of S-1, docetaxel, cisplatin and trastuzumab combination chemotherapy (DCS-T) in patients with HER2-positive unresectable metastatic gastric cancer

Feasibility study of S-1, docetaxel, cisplatin and trastuzumab combination chemotherapy (DCS-T) in patients with HER2-positive unresectable metastatic gastric cancer - Feasibility study of S-1, docetaxel, cisplatin and trastuzumab combination chemotherapy (DCS-T) in patients with HER2-positive unresectable metastatic gastric cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005603

Enrollment

Registered

2011-06-15

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Treatment with docetaxel (50mg/m2), CDDP (60mg/m2), S-1 (80mg/m2) and trastuzumab (6mg/kg) combination chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Written informed consent. 2)Histologicaly (cytologically) proven gastric cancer. 3)HER2 positive by IHC or FISH method 4)Unresectable gastric cancer. 5)To have measurable lesions. 6)No prior chemotherapy or no influence of prior therapy. 7)Tolerable function of bone marrow, liver and kidney. 8)LVEF more than 50% 9)PS 0 - 1. 10)Expected survival for 3 months. 11)Possible oral intake.

Exclusion criteria

Exclusion criteria: 1)History of hypersensitivity to DCS. 2)Contraindication to TXT, CDDP, S-1, G-CSF. 3)Infectious disease. 4)Severe compliaction. 5)Neuropathy greater than grade 2. 6)Brain metastasis with clinical symptoms. 7)Watery diarea. 8)Active double cancer. 9)Persons to be pregnant or to make pregnant.

Design outcomes

Primary

Measure	Time frame
feasibility	—

Countries

Japan

Contacts

Public ContactHiroshi Miyamoto

Tokushima University Hospital Department of Gastroenterology

miyamoto.hiroshi@tokushima-u.ac.jp088-633-7124

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026